Martin Hoyle

Professor

  • 1235 Citations
  • 21 h-Index
20042022
If you made any changes in Pure these will be visible here soon.

Research Outputs 2004 2019

  • 1235 Citations
  • 21 h-Index
  • 47 Article
  • 19 Commissioned report
  • 1 Other report
  • 1 Review article
2019

Therapeutic monitoring of TNF-alpha inhibitors in rheumatoid arthritis

Tikhonova, I., Yang, H., Salmon, A., Bello, S., Peters, J., Robinson, S., Rezaei, M., Dodman, S., Coelho, H., Kharechko, A., Haigh, R., Jani, M., McDonald, T. J., Hoyle, M. & Logan, S., 2019, University of Exeter. 425 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

Three biomarker tests to help diagnose preterm labour: a systematic review and economic evaluation

Peninsula Technology Assessment Group (PenTAG), Varley-Campbell, J., Mújica-Mota, R., Coelho, H., Ocean, N., Barnish, M., Packman, D., Dodman, S., Cooper, C., Snowsill, T., Kay, T., Liversedge, N., Parr, M., Knight, L., Hyde, C., Shennan, A. & Hoyle, M., Mar 2019, In : Health Technology Assessment. 23, 13, p. 1-226 226 p.

Research output: Contribution to journalArticleResearch

Open Access
File
Premature Obstetric Labor
Fibronectins
Quality-Adjusted Life Years
Cost-Benefit Analysis
Routine Diagnostic Tests
2018

Benralizumab for treating severe asthma: A Single Technology Appraisal

Tikhonova, I., Long, L., Ocean, N., Barnish, M., Robinson, S., Nikram, E., Bello, S., Dodman, S., Halpin, D. & Hoyle, M., 2018, University of Exeter. 223 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

Brigatinib for treating ALK-positive non-small-cell lung cancer after crizotinib [ID1328]: A Single Technology Appraisal

Griffin, E., Barnish, M., Packman, D., Coelho, H., Matthews, J., Dodman, S., Robinson, S., Dangoor, A., Dorey, N. & Hoyle, M., 2018, University of Exeter. 189 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

Economic analysis of the first-line treatment with cetuximab or panitumumab for RAS wild-type metastatic colorectal cancer in England

Tikhonova, I. A., Huxley, N., Snowsill, T., Crathorne, L., Varley-Campbell, J., Napier, M. & Hoyle, M., Jul 2018, In : PharmacoEconomics. 36, 7, p. 837-851 15 p.

Research output: Contribution to journalArticleResearchpeer-review

oxaliplatin
Leucovorin
irinotecan
Fluorouracil
Sarcoma

EMA and NICE appraisal processes for cancer drugs: current status and uncertainties

Dickson, R., Boland, A., Duarte, R., Kotas, E., Woolacott, N., Hodgson, R., Riemsma, R., Grimm, S., Ramaekers, B., Joore, M., Büyükkaramikli, N., Kaltenthaler, E., Stevenson, M., Pandor, A., Edwards, S., Hoyle, M., Shepherd, J., Armoiry, X. & Brazzelli, M., 1 Aug 2018, In : Applied Health Economics and Health Policy. 16, 4, p. 429-432 4 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File

Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis

Mujica-Mota, R., Varley-Campbell, J., Tikhonova, I., Cooper, C., Griffin, E., Haasova, M., Peters, J., Lucherini, S., Talens-Bou, J., Long, L., Sherriff, D., Napier, M., Ramage, J. & Hoyle, M., Sep 2018, In : Health Technology Assessment. 22, 49, p. 1-325 325 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Lutetium
Neuroendocrine Tumors
Cost-Benefit Analysis
Disease Progression
Quality-Adjusted Life Years

Olaratumab in combination with doxorubicin for treatment of advanced soft tissue sarcoma: An Evidence Review Group perspective of a National Institute for Health and Care Excellence Single Technology Appraisal

Tikhonova, I. A., Jones-Hughes, T., Dunham, J., Warren, F. C., Robinson, S., Stephens, P. & Hoyle, M., Jan 2018, In : PharmacoEconomics. 36, 1, p. 39-49 11 p.

Research output: Contribution to journalArticleResearchpeer-review

National Institutes of Health (U.S.)
Sarcoma
Doxorubicin
Cost-Benefit Analysis
Quality-Adjusted Life Years
2017

Azacitidine for treating acute myeloid leukaemia with more than 30 % bone marrow blasts: An Evidence Review Group perspective of a National Institute for Health and Care Excellence Single Technology Appraisal

Tikhonova, I. A., Hoyle, M. W., Snowsill, T. M., Cooper, C., Varley-Campbell, J. L., Rudin, C. E. & Mujica Mota, R. E., Mar 2017, In : PharmacoEconomics. 35, 3, p. 363-373 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Azacitidine
National Institutes of Health (U.S.)
Acute Myeloid Leukemia
Quality-Adjusted Life Years
Cost-Benefit Analysis

Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma: A Single Technology Appraisal

Tikhonova, I., Jones-Hughes, T., Dunham, J., Warren, F., Robinson, S., Stephens, P. & Hoyle, M., 2017, University of Exeter. 167 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours: A Single Technology Appraisal

Jones-Hughes, T., Dunham, J., Robinson, S., Napier, M. & Hoyle, M., 2017, University of Exeter. 142 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

The clinical effectiveness and cost-effectiveness of cetuximab (review of technology appraisal no. 176) and panitumumab (partial review of technology appraisal no. 240) for previously untreated metastatic colorectal cancer: a systematic review and economic evaluation

Huxley, N., Crathorne, L., Varley-Campbell, J., Tikhonova, I., Snowsill, T., Briscoe, S., Peters, J., Bond, M., Napier, M. & Hoyle, M., Jun 2017, In : Health Technology Assessment. 21, 38, p. 1-294 294 p.

Research output: Contribution to journalReview articleResearchpeer-review

Open Access
File
irinotecan
oxaliplatin
Leucovorin
Fluorouracil
Cost-Benefit Analysis
2016

Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts: A Single Technology Appraisal

Mujica Mota, R., Varley-Campbell, J., Tikhonova, I., Cooper, C., Hoyle, M., Rudin, C. & Snowsill, T., 2016, University of Exeter. 145 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

Everolimus, lutetium-177 DOTATATE and sunitinib for treating unresectable or metastatic neuroendocrine tumours with disease progression

Varley-Campbell, J., Mujica Mota, R., Tikhonova, I., Cooper, C., Griffin, E., Haasova, M., Peters, J., Lucherini, S., Talens-Bou, J., Long, L., Sherriff, D., Napier, M., Ramage, J. & Hoyle, M., 2016, University of Exeter. 372 p.

Research output: Book/ReportCommissioned reportResearch

Open Access
Lutetium
Neuroendocrine Tumors
Disease Progression
Cost-Benefit Analysis
Quality-Adjusted Life Years

Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model

Jones-Hughes, T., Snowsill, T., Haasova, M., Coelho, H., Crathorne, L., Cooper, C., Mujica-Mota, R., Peters, J., Varley-Campbell, J., Huxley, N., Moore, J., Allwood, M., Lowe, J., Hyde, C., Hoyle, M., Bond, M. & Anderson, R., Aug 2016, In : Health Technology Assessment. 20, 62, p. 1-594 594 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Mycophenolic Acid
Economic Models
Immunosuppressive Agents
Kidney Transplantation
Tacrolimus

The effectiveness and cost-effectiveness of erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer treatment-induced anaemia (including review of technology appraisal no. 142): a systematic review and economic model

Crathorne, L., Huxley, N., Haasova, M., Snowsill, T., Jones-Hughes, T., Hoyle, M., Briscoe, S., Coelho, H., Long, L., Medina-Lara, A., Mujica-Mota, R., Napier, M. & Hyde, C., Feb 2016, In : Health Technology Assessment. 20, 13, p. 1-588 588 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Hematinics
Economic Models
Cost-Benefit Analysis
Anemia
Technology
2015

A model-based assessment of the cost-utility of strategies to identify Lynch syndrome in early-onset colorectal cancer patients

Snowsill, T., Huxley, N., Hoyle, M., Jones-Hughes, T., Coelho, H., Cooper, C., Frayling, I. & Hyde, C., 25 Apr 2015, In : BMC Cancer. 15, 10 p., 313.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Hereditary Nonpolyposis Colorectal Neoplasms
Colorectal Neoplasms
Costs and Cost Analysis
Quality-Adjusted Life Years
Ovariectomy

Cetuximab (review of TA176) and panitumumab (partial review of TA240) for the first line treatment of metastatic colorectal cancer [ID794]: Multiple Technology Appraisal (MTA)

Huxley, N., Crathorne, L., Varley-Campbell, J., Tikhonova, I., Snowsill, T., Briscoe, S., Peters, J., Bond, M., Napier, M. & Hoyle, M., 2015, University of Exeter. 24 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

Immunosuppressive therapy for kidney transplantation in adults (review of technology appraisal guidance 85): A systematic review and economic model

Jones-Hughes, T., Snowsill, T., Haasova, M., Coelho, H., Crathorne, L., Cooper, C., Mujica-Mota, R., Peters, J., Varley-Campbell, J., Huxley, N., Moore, J., Allwood, M., Lowe, J., Hyde, C., Hoyle, M., Bond, M. & Anderson, R., 2015, University of Exeter. 759 p.

Research output: Book/ReportCommissioned reportResearch

Open Access
2014

A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome

Snowsill, T., Huxley, N., Hoyle, M., Jones-Hughes, T., Coelho, H., Cooper, C., Frayling, I. & Hyde, C., 2014, In : Health Technology Assessment. 18, 58, p. 1-405 405 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Hereditary Nonpolyposis Colorectal Neoplasms
Cost-Benefit Analysis
Colorectal Neoplasms
Costs and Cost Analysis
Microsatellite Instability

Obinutuzumab in combination with chlorambucil for previously untreated chronic lymphocytic leukaemia: a critique of the submission from Roche

Hoyle, M., Long, L., Huxley, N., Crathorne, L., Briscoe, S. & Rudin, C., 2014, University of Exeter. 190 p.

Research output: Book/ReportCommissioned reportResearch

Open Access
2013

Bosutinib for previously treated chronic myeloid leukaemia: a single technology appraisal

Hoyle, M., Snowsill, T., Haasova, M., Cooper, C. & Rudin, C., 2013, University of Exeter. 304 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

Complete cytogenetic response and major molecular response as surrogate outcomes for overall survival in first-line treatment of chronic myelogenous leukemia: a case-study for technology appraisal on the basis of surrogate outcomes evidence

Ciani, O., Hoyle, M., Pavey, T., Cooper, C., Garside, R., Rudin, C. & Taylor, R., 2013, In : Value in Health. 16, 6, p. 1081-1090 10 p.

Research output: Contribution to journalArticleResearchpeer-review

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cytogenetics
Technology
Survival
Leukemia, Myeloid, Chronic Phase

Cost-effectiveness of cetuximab, cetuximab plus irinotecan, and panitumumab for 3rd- and further lines of treatment for KRAS wild-type patients with metastatic colorectal cancer

Hoyle, M., Peters, J., Crathorne, L., Jones-Hughes, T., Cooper, C., Napier, M. & Hyde, C., 2013, In : Value in Health. 16, 2, p. 288-296 9 p.

Research output: Contribution to journalArticleResearchpeer-review

irinotecan
Cost-Benefit Analysis
Colorectal Neoplasms
Quality-Adjusted Life Years
Therapeutics

Evolution of a cost-utility model of donepezil for Alzheimer's disease

Peters, J., Anderson, R., Hoyle, M. & Hyde, C., 2013, In : International Journal of Technology Assessment in Health Care. 29, 2, p. 147-154 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Uncertainty
Alzheimer Disease
Costs and Cost Analysis
Health Care Costs
Drug Costs

Evolution of the evidence on the effectiveness and cost-effectiveness of acetylcholinesterase inhibitors and memantine for Alzheimer’s disease: systematic review and economic model

Hyde, C., Peters, J., Bond, M., Rogers, G., Hoyle, M., Anderson, R., Jeffreys, M., Davis, S., Thokala, P., Wailoo, A. & Moxham, T., 2013, In : Age and Ageing. 42, 1, p. 14-20 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Rivastigmine
Memantine
Economic Models
Cholinesterase Inhibitors
Cost-Benefit Analysis

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer

Joulain, F., Proskorovsky, I., Allegra, C., Tabernero, J., Hoyle, M., Iqbal, S. & Van Cutsem, E., 2013, In : British Journal of Cancer. 109, 7, p. 1735–1743 9 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Colorectal Neoplasms
Placebos
Survival
oxaliplatin
irinotecan
Open Access
File
Economic Models
Combination Drug Therapy
irinotecan
Cost-Benefit Analysis
Colorectal Neoplasms
2012

Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses

Pavey, T., Hoyle, M., Ciani, O., Crathorne, L., Jones-Hughes, T., Cooper, C., Osipenko, L., Venkatachalam, M., Rudin, C., Ukoumunne, O., Garside, R. & Anderson, R., 2012, In : Health Technology Assessment. 16, 42, p. 1-277 277 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Economics
Cytogenetics
Cost-Benefit Analysis
Quality-Adjusted Life Years

Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid Leukaemia: a systematic review and economic evaluation

Rogers, G., Hoyle, M., Thompson-Coon, J., Moxham, T., Liu, Z., Pitt, M. & Stein, K., 2012, In : Health Technology Assessment. 16, 22, p. 1-409 409 p.

Research output: Contribution to journalArticleResearch

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cost-Benefit Analysis
Blast Crisis
Leukemia, Myeloid, Chronic Phase
National Institutes of Health (U.S.)

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of mild to moderate Alzheimer’s disease (review of TA111): a systematic review and economic model

Bond, M., Rogers, G., Peters, J., Anderson, R., Hoyle, M., Miners, A., Moxham, T., Davis, S., Thokala, P., Wailoo, A., Jeffreys, M. & Hyde, C., 2012, In : Health Technology Assessment. 16, 21, p. 1-469 469 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Rivastigmine
Galantamine
Memantine
Economic Models
Quality-Adjusted Life Years
2011

Accounting for the drug life cycle and future drug prices in cost-effectiveness analysis

Hoyle, M., 2011, In : PharmacoEconomics. 29, 1, p. 1-15 15 p.

Research output: Contribution to journalArticleResearchpeer-review

Life Cycle Stages
Cost-Benefit Analysis
Pharmaceutical Preparations
New Zealand
Costs and Cost Analysis

Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or –intolerant chronic phase chronic myeloid leukaemia

Hoyle, M., Rogers, G., Moxham, T., Liu, Z. & Stein, K., 2011, In : Value in Health. 14, 8, p. 1057–1067 11 p.

Research output: Contribution to journalArticleResearchpeer-review

Leukemia, Myeloid, Chronic Phase
Cost-Benefit Analysis
Quality-Adjusted Life Years
Interferon-alpha
Costs and Cost Analysis

Dasatinib, nilotinib, and standard dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses

Hoyle, M., Pavey, T., Ciani, O., Crathorne, L., Jones-Hughes, T., Cooper, C., Osipenko, L., Venkatachalam, M., Rudin, C., Ukoumunne, O., Garside, R. & Anderson, R., 2011, University of Exeter. 242 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

Improved curve fits to summary survival data: application to economic evaluation of health technologies

Hoyle, M. & Henley, W., 2011, In : BMC Medical Research Methodology. 11, 14 p., 139.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Biomedical Technology
Cost-Benefit Analysis
Survival
Least-Squares Analysis
Interferon-alpha

Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK

Hoyle, M., Crathorne, L., Garside, R. & Hyde, C., 2011, In : Health Technology Assessment. 15, Suppl. 1, p. 61-67 7 p.

Research output: Contribution to journalArticleResearch

Open Access
File
B-Cell Chronic Lymphocytic Leukemia
Survival
Cost-Benefit Analysis
Leukemia
National Institutes of Health (U.S.)

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation

Thompson-Coon, J., Hoyle, M., Green, C., Liu, Z., Welch, K., Moxham, T. & Stein, K., 2010, In : Health Technology Assessment. 14, 2, p. 1-208 208 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Renal Cell Carcinoma
Interferons
Cost-Benefit Analysis
Disease-Free Survival
Quality-Adjusted Life Years

Cost-effectiveness of sorafenib for second-line treatment of advanced renal cell carcinoma

Hoyle, M., Green, C., Thompson-Coon, J., Liu, Z., Welch, K., Moxham, T. & Stein, K., 2010, In : Value in Health. 13, 1, p. 55-60 6 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Cost-Benefit Analysis
Quality-Adjusted Life Years
Costs and Cost Analysis
Therapeutics

Cost-effectiveness of temsirolimus for first line treatment of advanced renal cell carcinoma

Hoyle, M., Green, C., Thompson-Coon, J., Liu, Z., Welch, K., Moxham, T. & Stein, K., 2010, In : Value in Health. 13, 1, p. 61-68 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Renal Cell Carcinoma
Cost-Benefit Analysis
Quality-Adjusted Life Years
Costs and Cost Analysis
Interferon-alpha

Historical lifetimes of drugs in England: application to value of information and cost-effectiveness analyses

Hoyle, M., 2010, In : Value in Health. 13, 8, p. 885-892 8 p.

Research output: Contribution to journalArticleResearchpeer-review

England
Cost-Benefit Analysis
Pharmaceutical Preparations
Biomedical Technology
Technology

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease (review of TA111): a systematic review and economic model

Bond, M., Rogers, G., Peters, J., Anderson, R., Hoyle, M., Miners, A., Moxham, T., Davis, S., Thokala, P., Wailoo, A., Jeffreys, M. & Hyde, C., 2010, University of Exeter. 403 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

Whose costs and benefits? Why economic evaluations should simulate both prevalent and all future incident patient cohorts

Hoyle, M. & Anderson, R., 2010, In : Medical Decision Making. 30, 4, p. 426-437 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Cost-Benefit Analysis
Biomedical Technology
Chronic Disease
Costs and Cost Analysis
2009

Maximum feasible distance of windborne cross-pollination in Brassica napus: A ‘mass budget’ model

Hoyle, M. & Cresswell, J. E., 2009, In : Ecological Modelling. 220, 8, p. 1090–1097 8 p.

Research output: Contribution to journalArticleResearchpeer-review

pollination
gene
pollen
budget
canola

Sunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectiveness

Thompson-Coon, J. S., Liu, Z., Hoyle, M., Rogers, G., Green, C., Moxham, T., Welch, K. & Stein, K., 2009, In : British Journal of Cancer. 101, p. 238-243 6 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Renal Cell Carcinoma
Disease-Free Survival
Interferon-alpha
Randomized Controlled Trials
Markov Chains

Sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer

Bond, M., Hoyle, M., Moxham, T., Napier, M. & Anderson, R., 2009, In : Health Technology Assessment. 13, Suppl. 2, p. 69-74 6 p., 10.

Research output: Contribution to journalArticleResearch

Open Access
File

The clinical and cost-effectiveness of sunitinib for the treatment of gastrointestinal stromal tumours: a critique of the submission from Pfizer

Bond, M., Hoyle, M., Moxham, T., Napier, M. & Anderson, R., 2009, University of Exeter. 101 p.

Research output: Book/ReportCommissioned reportResearch

Open Access

The effectiveness and cost-effectiveness of cochlear implants for severe to profound deafness in children and adults: a systematic review and economic model

Bond, M., Mealing, S., Anderson, R., Elston, J., Weiner, G., Taylor, RS., Hoyle, M., Liu, Z., Price, A. & Stein, K., 2009, In : Health Technology Assessment. 13, 44, p. 1-196 196 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Economic Models
Cochlear Implants
Deafness
Cost-Benefit Analysis
Hearing Aids